Mitral Regurgitation - Valvular Heart Disease Guidelines

Valvular Heart Disease

ACC/AHA Valvular Heart Disease - Mitral Regurgitation GUIDELINES Apps brought to you charge courtesy of Guideline Central and Abbott Vascular.

Issue link: https://eguideline.guidelinecentral.com/i/362036

Contents of this Issue

Navigation

Page 49 of 59

Figure 10. Anticoagulation of Pregnant Patients With Mechanical Valves Pregnant Patient With Mechanical Valve Continue warfarin with close INR monitoring (IIa) Baseline warfarin dose >5 mg daily Pregnancy and VHD OR Dose-adjusted LMWH ≥2x daily (target anti-Xa level 0.8-1.2 U/mL 4-6 h postdose) (IIb) OR Dose-adjusted continuous infusion of UFH (with aPTT ≥2x control) (IIb) First trimester Dose-adjusted LMWH ≥2x daily (target anti-Xa level 0.8-1.2 U/mL 4-6 h postdose) (IIa) OR Dose-adjusted continuous infusion of UFH (with aPTT ≥2x control) (IIa) Second and third trimesters Before planned vaginal delivery Discontinue warfarin and dose- adjusted continuous infusion of UFH (with aPTT ≥2x control) (I) Baseline warfarin dose ≤5 mg daily 48 erapeutic anticoagulation with frequent monitoring (I) Warfarin to goal INR plus ASA 75-100 mg QD (I) First trimester

Articles in this issue

view archives of Mitral Regurgitation - Valvular Heart Disease Guidelines - Valvular Heart Disease